Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Total Non-Current Liabilities (2023 - 2025)

CG Oncology filings provide 3 years of Total Non-Current Liabilities readings, the most recent being $37.2 million for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 73.9% to $37.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $37.2 million, a 73.9% increase, with the full-year FY2025 number at $37.2 million, up 73.9% from a year prior.
  • Total Non-Current Liabilities hit $37.2 million in Q4 2025 for CG Oncology, down from $38.5 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $38.5 million in Q3 2025 to a low of $14.1 million in Q4 2023.
  • Median Total Non-Current Liabilities over the past 3 years was $29.3 million (2024), compared with a mean of $27.8 million.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 51.42% in 2024 and later soared 73.9% in 2025.
  • CG Oncology's Total Non-Current Liabilities stood at $14.1 million in 2023, then soared by 51.42% to $21.4 million in 2024, then soared by 73.9% to $37.2 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $37.2 million (Q4 2025), $38.5 million (Q3 2025), and $21.4 million (Q4 2024) per Business Quant data.